Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder

Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01369459

Acronym

MIP

Enrollment

Registered

2011-06-09

Start date

2011-11-30

Completion date

2014-12-31

Last updated

2015-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder

Keywords

Comorbid, ADHD, SUD, ASU

Brief summary

The goal of this project is to develop and test a brief protocol designed to systematically integrate pharmacological interventions for Attention Deficit Hyperactivity Disorder (ADHD) into behavioral treatment services for adolescent substance users with co-morbid ADHD in everyday care. Primary study aims will yield proof-of-concept data on MIP feasibility and fidelity in usual care and evidence of MIP impact on psychiatric and behavioral services utilization, medication acceptance and compliance, and satisfaction with treatment services.

Interventions

BEHAVIORALMIP Protocol

We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

13 Years to 17 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 13-17 years * Caregiver able to participate in treatment * One day of alcohol use to intoxication or illegal drug use in the past 30 days (or 30 days prior to living in a controlled environment) * endorsement of one or more DSM-IV symptoms of Substance Use or Alcohol Dependence/Abuse * meet ASAM criteria for outpatient substance use treatment * meet DSM-IV criteria for ADHD (with or without onset prior to age 7) * not enrolled in any behavioral treatment

Exclusion criteria

* MDD * Bipolar Disorder * Mental Retardation * PDD * medical or psychiatric illness requiring hospitalization * current psychotic features * currently suicidal

Design outcomes

Primary

Measure	Time frame	Description
Mini International Neuropsychiatric Interview (MINI) Version 5.0	Follow-up in 3 months	MINI is a structured diagnostic interview that assesses DSM-IV diagnoses in adolescents and is designed for administration by lay interviewers. Adolescents and caregivers will complete the Inattentive and Hyperactive/Impulsive scales.

Secondary

Measure	Time frame	Description
Behavior Rating Inventory of Executive Function (BRIEF)	Follow-up at 3-months	The BRIEF is a parent-report measure of behavioral problems linked to executive functioning and commonly observed in ADHD youth. The BRIEF has been validated on ADHD outpatient samples and teens with mixed clinical diagnoses. This study will use 4 scales: Inhibition, Behavioral Shift, Emotional Control, Plan/Organize.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026